Anzeige
Mehr »
Login
Sonntag, 22.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Fed senkt Zinsen, Gold steigt: Eine Aktie, die vom Anstieg des Goldpreises betroffen sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
235 Leser
Artikel bewerten:
(1)

Tracelink, Inc.: TraceLink Becomes First Solution Provider to Secure All 16 GS1 US Conformance Trustmarks for EPCIS File Support

BOSTON, Aug. 26, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, proudly announces it has become the first and only solution provider to secure all 16 GS1 US Conformance Trustmarks for EPCIS file support. These trustmarks certify that a company's systems meet stringent criteria for accurately and securely exchanging traceability data, ensuring compliance with the Drug Supply Chain Security Act (DSCSA) requirements for tracking and tracing prescription drugs through the supply chain. This landmark achievement sets a new industry standard in the U.S. pharmaceutical supply chain's efforts to meet the DSCSA requirements.


This comprehensive certification encompasses 7 trustmarks supporting manufacturers to downstream trading partners and 9 trustmarks aiding wholesalers to dispensers. The attainment of all available trustmarks underlines TraceLink's commitment to excellence and compliance in the pharmaceutical industry, providing assurance that the EPCIS messages sent on behalf of our clients-manufacturers, wholesalers, and dispensers-are in full compliance with the application standards set by GS1 US, the publisher of the GS1 US Implementation Guideline: Applying GS1 Standards for DSCSA and Traceability, Release 1.2. This ensures that TraceLink customers can seamlessly track and trace their products, reducing operational risks, enhancing supply chain transparency, and ultimately improving patient safety.

Focused on Standards and Compliance

The GS1 US Rx EPCIS Conformance Testing Program plays a crucial role in the pharmaceutical supply chain, ensuring the interoperability and compliance of data exchanges required by the DSCSA.

"TraceLink's dedication to standards has been a cornerstone of our mission for over 15 years," said Shabbir Dahod, President and CEO of TraceLink. "Our active participation and leadership in various standards working groups, such as the GS1 US Healthcare Executive Leadership Team, GS1 Global Healthcare Leadership Team, and the GS1 Global Architecture Team, make evident our commitment to driving massive adoption and interoperability across the supply chain. Our own Elizabeth Waldorf, Director of Global Traceability and Standards, has served as co-chair of the GS1 US RxSecureSupplyChain Workgroup and the GS1 EPCIS/CBV Standard MSWG and Visibility Standards Mission Group and was also recognized with the 2022 GS1 Ken Traub Industry Award. Our ongoing investment in these initiatives is crucial for ensuring the delivery of safe, effective, and authentic medicines to patients worldwide."

Utilizing the DSCSA Stabilization Period

During the Enhanced Drug Distribution Security Stabilization Period from November 2023 to November 2024, the FDA recommended using this time to "implement, troubleshoot, and mature their systems and processes while supporting the continued availability of products to patients." Achieving all 16 GS1 US Conformance Trustmarks is a great demonstration of how to best utilize this stabilization period, showcasing our commitment to interoperability through enhanced drug distribution and secure electronic tracing of products at the package level.

A Commitment to Excellence

"According to GS1 US, the goal of the Rx EPCIS Conformance Testing Program is to support and streamline trading partner on-boarding with a mechanism to provide a level of confidence about readiness, implementation quality and consistency. The voluntary program is designed to validate that an EPCIS event file follows the format and structure defined in the GS1 US Implementation Guideline to support interoperable EPCIS baseline functionality for the purposes of serialized item data exchanges." TraceLink's commitment to aligning with GS1 standards ensures a reliable and interoperable pharmaceutical supply chain, benefiting all stakeholders from manufacturers to dispensers.

As we celebrate this milestone, we continue to innovate and support our customers through exceptional service and compliance expertise. We have created solutions, such as Digital Recalls, to expand the usage of EPCIS data, enhancing patient safety.

For more information about TraceLink and our compliance solutions, please visit our website at https://www.tracelink.com/legal-and-trust/certifications.

For more information about the GS1 US Rx EPCIS Conformance Testing Program visit: GS1 US Rx EPCIS Conformance Testing Program.

Logo - https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tracelink-becomes-first-solution-provider-to-secure-all-16-gs1-us-conformance-trustmarks-for-epcis-file-support-302230536.html

© 2024 PR Newswire
Besser als NVIDIA! 3 KI- Favoriten mit riesigem Potenzial

Erleben Sie die KI-Revolution und sichern Sie sich gigantische Gewinne!

Nutzen Sie die einmalige Gelegenheit, die Ihnen die Künstliche Intelligenz bietet! Unser exklusiver Aktienreport enthüllt drei unglaublich aussichtsreiche KI-Aktien, die von der bahnbrechenden Entwicklung in diesem Sektor massiv profitieren können.

Warum sollten Sie dabei sein?

Weil eine Investition in KI-Unternehmen nicht nur Stabilität bringt, sondern auch das Potenzial hat, Ihr Depot explosionsartig wachsen zu lassen. Die letzten Jahre haben bewiesen: Wer auf KI setzt, kann außergewöhnliche Gewinne einfahren. Jetzt, nach einer kurzen Konsolidierungsphase, öffnen sich wieder sensationelle Einstiegsmöglichkeiten.

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche KI-Aktien das größte Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen die besten Investments im KI-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.